Wall Street analysts expect Steris (STE) to post quarterly earnings of $2.32 per share in its upcoming report, which indicates a year-over-year increase of 4.5%. Revenues are expected to be $1.38 billion, down 1.1% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings release, it is of utmost importance to ...

STERIS plc (STE) is expected to release third-quarter fiscal 2025 results on Feb. 6, before market open. Find the latest EPS estimates and surprises on Zacks Earnings Calendar.In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.14, which beat the Zacks Consensus Estimate by 1.4%. STE beat on earnings in each of the trailing four quarters, delivering an average surprise of 1.18%.STE’s Q3 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $1.38 billion, sugges ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? ...

STERIS’ (STE) new acquisitions and partnerships strengthen its product offerings. Yet macroeconomic challenges continue to dampen growth. The stock carries a Zacks Rank #3 (Hold) currently.Factors Driving STERIS' GrowthSTERIS’ Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to maintain that equipment, repair reusable procedural instruments and outsource instrument reproce ...

DUBLIN, IRELAND , Jan. 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2025 third quarter financial results at 9:00 a.m. ET on February 6, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be ...

Core Points - A jury trial against Isomedix Operations, Inc., a subsidiary of STERIS plc, ended in a mistrial on January 17, 2025, after being ongoing since December 4, 2024 [1][2] - The case involves claims of personal injury due to ethylene oxide emissions from a sterilization facility in Waukegan, Illinois, which Isomedix operated from 2005 to 2008 [2] - The court will schedule a re-trial at a later date following the mistrial declaration [2] Company Actions - Isomedix plans to vigorously defend against the allegations related to ethylene oxide operations and emissions from the Waukegan facility [3] - The company has invested in its facilities and implemented processes that meet or exceed applicable environmental regulatory standards [3] Company Overview - STERIS is a leading global provider of products and services focused on infection prevention and patient care [4] - The company emphasizes creating a healthier and safer world through innovative healthcare and life sciences products and services [4]

STERIS (STE) new acquisitions and partnerships have been strengthening its product offerings. However, macroeconomic challenges continue to dampen growth. The stock carries a Zacks Rank #3 (Hold).Factors Driving STERIS' GrowthSTERIS frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses. In recent years, the company has made several large acquisitions. It purchased the surgical instrumentation, laparoscopic instrumentation and sterilization container assets f ...

Core Insights - STERIS plc's growth in fiscal Q2 2025 is primarily driven by its Healthcare business and the positive outlook for its Applied Sterilization Technologies (AST) segment [1][2] Company Performance - The Healthcare segment reported a revenue growth of 9% year over year, with consumable revenues increasing by 12% and service revenues by 14%, attributed to higher procedure volumes in the U.S. and market share gains [4] - The AST division experienced a 9% reported growth year over year, driven by a 6% increase in service revenues and improved capital equipment revenues [5] - STERIS has a market capitalization of $21.15 billion and has consistently surpassed earnings estimates over the past four quarters, with an average surprise of 1.18% [2] Financial Metrics - The Zacks Consensus Estimate for STERIS' fiscal 2025 earnings has increased by 0.9% to $9.10 per share, while the revenue estimate stands at $5.48 billion, indicating a 0.8% growth from fiscal 2024 [9] Challenges - Foreign currency risks pose a significant concern, with nearly 30% of revenues generated outside the U.S., leading to a negative impact of approximately $2.1 million in the fiscal second quarter due to currency fluctuations [7] - The competitive landscape is intense, with STERIS facing competition from both large companies with extensive product portfolios and smaller firms with limited offerings [8]

STERIS (STE) continues to gain from a strong rebound in procedure volumes in the United States within the Healthcare business. New acquisitions and partnerships should strengthen its product offerings. Yet macroeconomic challenges continue to dampen growth. The stock carries a Zacks Rank #3 (Hold) currently.Factors Driving STERIS' GrowthSTERIS’ Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. F ...

In my previous ‘Hold’ rating on STERIS (NYSE: STE ) in September 2024, I expressed my concern about their overvalued stock price. Since then, the stock price has dropped by more than 10%, significantly underperforming the index (Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for ...